SGTX News and Press, Sigilon Therapeutics Inc. From 06/29/23

Lilly to Acquire Sigilon Therapeutics PR Newswire INDIANAPOLIS and CAMBRIDGE, Mass. , June 29, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced a definitive agreement for Lilly ...

2023-05-25 12:45:34 ET Gainers: Beamr Imaging ( BMR ) +108% . Nano Labs ( NA ) +57% . Team ( TISI ) +44% . Wireless Telecom Group ( WTT ) +30% . Atento ( ATTO ) +29% . NVIDIA Corporation ( NVDA ) +26% . Super Micr...

2023-05-22 08:00:21 ET Sigilon Therapeutics ( NASDAQ: SGTX ) said on Monday that it will effect a 13-for-1 reverse stock split, effective the opening of trading on May 23. The company's shareholders had approved an amendment to the fifth amended and restated certificate of inc...

CAMBRIDGE, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced it will effect a one-for-13 reverse stock split of its issued and outstanding common stock. Sigilon stockholders approved an amendment to Sigilon’s Fifth Amended and Restated Certif...

2023-05-09 08:53:13 ET Sigilon Therapeutics press release ( NASDAQ: SGTX ): Q1 GAAP EPS of -$0.23 in-line. Revenue of $4.86M (+53.3% Y/Y) beats by $1.76M . For further details see: Sigilon Therapeutics GAAP EPS of -$0.23 in-line, revenue of $4.86M beats by $1...

SIG-002, Sigilon’s lead program for the treatment of diabetes, transitioning to IND-enabling and NHP studies in the second half of 2023 Pipeline prioritization extends anticipated cash runway into 2025 CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics,...

Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor PR Newswire CHICAGO , May 2, 2023 /PRNewswire/ -- Dimension Inx, a biomaterials platform company developing therapeutics ...

CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for acute and chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Exe...

2023-03-14 16:53:16 ET Sigilon Therapeutics press release ( NASDAQ: SGTX ): Q4 GAAP EPS of -$0.21 beats by $0.17 . Revenue of $2.64M (+32.7% Y/Y) misses by $0.03M . For further details see: Sigilon Therapeutics GAAP EPS of -$0.21 beats by $0.17, revenue o...

Sigilon Therapeutics press release ( NASDAQ: SGTX ): Q3 GAAP EPS of -$0.27 beats by $0.15 . Revenue of $4.25M (+117.9% Y/Y) beats by $1.75M . For further details see: Sigilon Therapeutics GAAP EPS of -$0.27 beats by $0.15, revenue of $4.25M beats by $1.75...